DRG Market Assessment reports

The treatment of osteoporosis represents a large market that is dominated by the bisphosphonate drug class. Although more-efficacious therapies are available, step therapy is commonplace, with…

No disease-modifying therapies are approved to treat primary Sjögren’s syndrome (pSS), a progressive, autoimmune disease characterized by sicca symptoms, which are caused by chronic inflammation…

Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (AD) have progressively moved earlier in the disease…

Market Outlook Targeted therapies are changing the treatment paradigm for ovarian cancer in the top 5 European markets (France, Germany, Italy, Spain, UK). Roche’s Avastin and small-molecule…

Chemotherapy remains the standard of care for the treatment of ovarian cancer, but new classes of drugs such as angiogenesis inhibitors and, more recently, PARP inhibitors have entered the…

MARKET OUTLOOK Sarcoidosis is an inflammatory disease of unclear etiology. It is characterized by tissue infiltration of granulomas, most commonly into the lung and lymph nodes, but the skin,…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to…

Overactive bladder is a common condition that manifests as a complex set of symptoms in the lower urinary tract and affects both men and women. It is characterized by sudden urges to urinate and…

MARKET OUTLOOK Following approval by the FDA in 2015, AbbVie’s Humira (adalimumab) became (and remains) the only approved therapy for the treatment of hidradenitis suppurativa. Humira is…

Hypertriglyceridemia is characterized by elevated triglyceride (TG) levels. In addition to lifestyle changes, current treatment focuses on improving patients’ TG levels with the aim to reduce the…

Epidemiology of Pediatric Ischemic Stroke in EU5. Table of Contents:   1. Stroke Literature Review Data – EU5 2. Stroke Literature Review Data – Non-EU5 3. Stroke Hospital Discharge…

Topical corticosteroids, topical calcineurin inhibitors, and systemic immunosuppressants have historically served as the backbone of AD treatment. The launch of the first targeted biology therapy…